Test Catalog

Test Id : ACC

Adrenal Mass Panel, 24 Hour, Urine

Useful For
Suggests clinical disorders or settings where the test may be helpful

Aids in assessing malignancy in adrenal masses

 

May aid in improving diagnostic and prognostic prediction and dissect disease mechanisms for the following applications:

-Diagnostic assessment and follow up of adrenal cortical carcinoma (ACC)

-Differential diagnostic assessment of adrenal tumors

-Additional assessment related to Cushing syndrome, subclinical Cushing syndrome, primary aldosteronism, inborn errors of steroidogenesis, polycystic ovary syndrome

 

This test is not useful for establishing eligibility for a specific treatment as results must be interpreted in conjunction with the clinical status of the patient.

Highlights

This test offers an accurate, rapid, cost-effective, non-invasive tool to better assess malignant adrenal tumors and assists clinicians in determining whether an adrenal mass is benign or malignant.

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with a clinical risk assessment based on clinical data before integration with biochemical steroid data to assess the probability of a malignant adrenal cortical carcinoma (ACC) or other malignancy (sarcoma, lymphoma, other) as well as the probability of a benign mass (adenoma, myelolipoma, cyst, other).

 

Clinical data includes age at diagnosis, gender, mode of discovery and hormonal status along with tumor diameter and an unenhanced CT density measurement of the tumor (in Hounsfield units).

 

Steroids and their metabolites are extracted, analyzed, quantitated, and reported. Each reported analyte also includes a Z-score. An integrated risk assessment based on clinical data in combination with biochemical steroid data is reported to assess the probability of a malignant ACC or other malignancy as well as the probability of a benign mass.

 

See Adrenal Mass Panel Clinical Data Definition of Malignancy Predictors in Special Instructions.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Method Name
A short description of the method used to perform the test

Liquid Chromatography-Tandem Mass Spectrometry, High-Resolution Accurate Mass (LC-MS/MS HRAM)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Adrenal Mass Panel, 24 Hr, U

Aliases
Lists additional common names for a test, as an aid in searching

Adrenal Cortical Carcinoma

Adrenal Cortical Adenoma

Androsterone

Etiocholanolone

Dehydroepiandrosterone

16a-OH-Dehydroepiandrosterone

5-Pregnenetriol

5-Pregnenediol

Tetrahydro-11-Corticosterone

Tetrahydro-11-Deoxycorticosterone

Pregnanediol

17a-OH-Pregnanolone

Pregnanetriol

Pregnanetriolone

Tetrahydrodeoxycortisol

Cortisol

6B-OH-Cortisol

Tetrahydrocortisol

5a-Tetrahydrocortisol

B-Cortol

11B-OH-Androsterone

11B-OH-Etiocholanolone

Cortisone

Tetrahydrocortisone

a-Cortolone

B-Cortolone

11-Oxoetiocholanolone

ACC

ACCSP

Steroid

Steroid Panel

SP25

sarcoma

lymphoma

benign mass

adenoma

myelolipoma

cyst

AN

ANN

ETIO

DHEA

16a-DHEA

5PT

5PD

THB

THDOC

PD

17HP

PT

PTONE

THS

6B-OH-CORT

THF

5a-THF

11B-OH-AN

11B-OH-ET

THE

11B-OXO-ET

ACA

ACTH

Adrenocorticotropic hormone

HRAM

11B-hydroxyandrosterone

11B-hydroxyetiocholanolone

11-OXO-ET

16a-hydroxydehydroepiandrosterone

17a-hydroxypregnanolone

6B-hydroxycortisol

aCortolone

tetrahydrocorticosterone

tetrahydrodeoxycorticosterone

CAH

Hydroxylase Deficiency

CAH21

CA21H

Congenital Adrenal hyperplasia

Corticosteroids

CYP21

11Beta-OH-AN

11Beta-hydroxyandrosterone

11Beta-OH-ET

11Beta-hydroxyetiocholanolone

16alpha-DHEA

16alpha-hydroxydehydroepiandrosterone

17alpha-hydroxypregnanolone

5alpha-tetrahydrocortisol

6Beta-OH-cort

6Beta-hydroxycortisol

alpha-Cortolone

Beta-Cortol

Beta-Cortolone

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with a clinical risk assessment based on clinical data before integration with biochemical steroid data to assess the probability of a malignant adrenal cortical carcinoma (ACC) or other malignancy (sarcoma, lymphoma, other) as well as the probability of a benign mass (adenoma, myelolipoma, cyst, other).

 

Clinical data includes age at diagnosis, gender, mode of discovery and hormonal status along with tumor diameter and an unenhanced CT density measurement of the tumor (in Hounsfield units).

 

Steroids and their metabolites are extracted, analyzed, quantitated, and reported. Each reported analyte also includes a Z-score. An integrated risk assessment based on clinical data in combination with biochemical steroid data is reported to assess the probability of a malignant ACC or other malignancy as well as the probability of a benign mass.

 

See Adrenal Mass Panel Clinical Data Definition of Malignancy Predictors in Special Instructions.

Specimen Type
Describes the specimen type validated for testing

Urine

Shipping Instructions

Ship specimens frozen.

Necessary Information

Collection duration and 24-hour volume is required.

The following information is required (NA or Not Applicable are not acceptable responses):

-Age at diagnosis (not offered for pediatric patients)

-Gender

-Mode of discovery (incidental, cancer staging, other)

-Tumor diameter (mm)

-Unenhanced CT (Hounsfield units)

-Hormonal excess (Yes, No)

If information is not provided, testing may be delayed or canceled.

If not ordering electronically, Adrenal Mass Panel Patient Information is required. See Special Instructions.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Supplies: Aliquot Tube, 5 mL (T465)

Container/Tube: Plastic urine tube

Specimen Volume: 4 mL

Collection Instructions:

1. Collect urine for a full 24 hours (required) and record the total volume.

2. Do not add preservatives. Specimens containing preservatives will be canceled.

3. Entire 24 hour collection must be mixed well prior to aliquoting into a 5 mL plastic tube.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Forms

Adrenal Mass Panel Patient Information is required, see Special Instructions.

Urine Preservative Collection Options

Note: The application of temperature controls must occur within 4 hours of completion of the collection.

 

Ambient

No

Refrigerate

OK

Frozen

OK

50% Acetic Acid

No

Boric Acid

No

Diazolidinyl Urea

No

6M Hydrochloric Acid

No

6M Nitric Acid

No

Sodium Carbonate

No

Thymol

No

Toluene

No

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

2 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis OK
Gross icterus OK
Specimens with preservatives Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Urine Frozen (preferred) 90 days
Refrigerated 14 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Aids in assessing malignancy in adrenal masses

 

May aid in improving diagnostic and prognostic prediction and dissect disease mechanisms for the following applications:

-Diagnostic assessment and follow up of adrenal cortical carcinoma (ACC)

-Differential diagnostic assessment of adrenal tumors

-Additional assessment related to Cushing syndrome, subclinical Cushing syndrome, primary aldosteronism, inborn errors of steroidogenesis, polycystic ovary syndrome

 

This test is not useful for establishing eligibility for a specific treatment as results must be interpreted in conjunction with the clinical status of the patient.

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with a clinical risk assessment based on clinical data before integration with biochemical steroid data to assess the probability of a malignant adrenal cortical carcinoma (ACC) or other malignancy (sarcoma, lymphoma, other) as well as the probability of a benign mass (adenoma, myelolipoma, cyst, other).

 

Clinical data includes age at diagnosis, gender, mode of discovery and hormonal status along with tumor diameter and an unenhanced CT density measurement of the tumor (in Hounsfield units).

 

Steroids and their metabolites are extracted, analyzed, quantitated, and reported. Each reported analyte also includes a Z-score. An integrated risk assessment based on clinical data in combination with biochemical steroid data is reported to assess the probability of a malignant ACC or other malignancy as well as the probability of a benign mass.

 

See Adrenal Mass Panel Clinical Data Definition of Malignancy Predictors in Special Instructions.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Approximately 80 million computerized tomography (CT) scans are performed in the United States every year. Adrenal tumors are found incidentally in about 5% of these scans. Most of these tumors will turn out to be benign, but a small fraction will be adrenal cortical carcinoma (ACC), a type of cancer with high mortality and frequent recurrence. Even for localized disease, the 5 year survival rates do not exceed 65%, and distant spread is associated with a greater than 90% mortality rate within that time period. Early diagnosis of a malignant adrenal mass is therefore imperative to assure timely and appropriate therapy.

 

Unfortunately, CT imaging alone is very limited in its ability to distinguish benign from malignant adrenal tumors since only very small and hypodense lesions can be easily dismissed as benign. The sizeable group of patients with larger or denser tumors ends up with an arduous workup that frequently includes additional imaging studies, hormonal testing, and biopsy. However, even the latter has both a high diagnostic false positive- and false negative rate, and ultimately the tumor is often resected, sometimes unnecessarily. On the other hand, the delays due to the diagnostic work might compromise optimal care for those tumors that prove malignant.

 

In addition, patients who are believed to probably not have adrenal cancer after their workup, and those who opt out of biopsy or surgery, often still require long-term follow up with regular re-imaging and repeated hormone testing, with resultant radiation exposure and high health care costs.

 

This adrenal mass panel is a noninvasive and more accurate test to diagnose malignant adrenal tumors, via urinary steroid profiling. It differentiates ACC, a rare and lethal tumor, from benign adrenocortical adenomas (ACA), including those that overproduce corticosteroids, or mineral steroids, or sex steroids, or those that are hormonally inactive. The test utilizes both clinical and laboratory data. The clinical parameters are age at diagnosis and sex of the patient, the size of the tumor by CT scanning and its x-ray density in Hounsfield units, whether it was detected incidentally or not, and whether there is evidence of hormone overproduction. All of this data are readily available for almost all patients with an adrenal mass, and are used by an algorithm to calculate the pretest probability of having ACC. The steroid profile testing is then performed and its results are added into the risk calculation algorithm to generate a posttest probability. The final result will provide the referring physicians a highly accurate probability for ACC and will thereby facilitate the optimal choice of further investigation, if any, based on an informed discussion between doctor and patient.

 

Understanding the Adrenal Glands

The human body has two adrenal glands, one above each kidney. Adrenal glands influence many processes and functions of our body, mainly through production of three types of steroid hormones:

-Mineralocorticoids (eg, aldosterone, which helps control blood pressure)

-Glucocorticoids (eg, cortisol, which is important for metabolism, immune response and stress)

-Sex Steroids (eg, DHEAS, a precursor of testosterone and estradiol)

 

These steroids are all synthesized from cholesterol via enzymes in the adrenal glands. In benign ACA, near-normal levels of precursor and bioactive steroids are produced. By contrast, ACC frequently shows abnormal patterns of steroid production. By measuring 25 different steroid metabolites, even subtle abnormalities can be detected. This is the basis for the assessment capability of profiling 25 steroids.

 

Epidemiology of Adrenal Tumors

Adrenal masses are found in 5% of the population. The prevalence increases with age, to around 10% in 70-year-old patients.

 

Although the majority of these tumors are benign, around 30% of adrenal tumors (>4cm) are malignant (most represented by ACCs), and the survival rate for these patients is very poor unless detected early.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Note: Due to the wide range of urine steroid metabolite concentrations seen in healthy individuals and their skewed distribution, the reference values are based on the back calculated +/- 3SD of log transformed data.

 

Males 18-49 years:

Androsterone: 182-29,212 mcg/24 hour

Etiocholanolone: 133-23,272 mcg/24 hour

Dehydroepiandrosterone: <5-81,554 mcg/24 hour

16a-OH-Dehydroepiandrosterone: 13-29,945 mcg/24 hour

5-Pregnenetriol: 23-7,328 mcg/24 hour

5-Pregnenediol: 13-2,823 mcg/24 hour

Tetrahydro-11-Corticosterone: 8-1,961 mcg/24 hour

Tetrahydro-11-Deoxycorticosterone: <5-316 mcg/24 hour

Pregnanediol: 12-3,812 mcg/24 hour

17a-OH-Pregnanolone: 15-2,466 mcg/24 hour

Pregnanetriol: 66-9,409 mcg/24 hour

Pregnanetriolone: <5-550 mcg/24 hour

Tetrahydrodeoxycortisol: 7-1520 mcg/24 hour

Cortisol: <5-903 mcg/24 hour

6B-OH-Cortisol: 13-2,303 mcg/24 hour

Tetrahydrocortisol: 152-22,723 mcg/24 hour

5a-Tetrahydrocortisol: 157-24,059 mcg/24 hour

B-Cortol: 30-5,115 mcg/24 hour

11B-OH-Androsterone: 108-11,987 mcg/24 hour

11B-OH-Etiocholanolone: 22-8,312 mcg/24 hour

Cortisone: 12-842 mcg/24 hour

Tetrahydrocortisone: 271-44,355 mcg/24 hour

a-Cortolone: 140-14,885 mcg/24 hour

B-Cortolone: 72-9,740 mcg/24 hour

11-Oxoetiocholanolone: 70-8,446 mcg/24 hour

 

Males > or =50 years:

Androsterone: 118-25,389 mcg/24 hour

Etiocholanolone: 127-15,640 mcg/24 hour

Dehydroepiandrosterone: 7-4,260 mcg/24 hour

16a-OH-Dehydroepiandrosterone: 11-6,183 mcg/24 hour

5-Pregnenetriol: 24-2,162 mcg/24 hour

5-Pregnenediol: 17-1,296 mcg/24 hour

Tetrahydro-11-Corticosterone: 16-1,674 mcg/24 hour

Tetrahydro-11-Deoxycorticosterone: <5-297 mcg/24 hour

Pregnanediol: 23-1,846 mcg/24 hour

17a-OH-Pregnanolone: 18-1,747 mcg/24 hour

Pregnanetriol: 115-5,432 mcg/24 hour

Pregnanetriolone: 5-221 mcg/24 hour

Tetrahydrodeoxycortisol: 12-1,277 mcg/24 hour

Cortisol: 12-597 mcg/24 hour

6B-OH-Cortisol: 22-2,406 mcg/24 hour

Tetrahydrocortisol: 331-19,009 mcg/24 hour

5a-Tetrahydrocortisol: 155-35,266 mcg/24 hour

B-Cortol: 56-3,541 mcg/24 hour

11B-OH-Androsterone: 142-13,135 mcg/24 hour

11B-OH-Etiocholanolone: 69-6,805 mcg/24 hour

Cortisone: 24-732 mcg/24 hour

Tetrahydrocortisone: 454-34,576 mcg/24 hour

a-Cortolone: 211-17,591 mcg/24 hour

B-Cortolone: 114-8,434 mcg/24 hour

11-Oxoetiocholanolone: 155-7,174 mcg/24 hour

 

Females 18-49 years:

Androsterone: 90-29,625 mcg/24 hour

Etiocholanolone: 127-24,568 mcg/24 hour

Dehydroepiandrosterone: <5-12,317 mcg/24 hour

16a-OH-Dehydroepiandrosterone: 5-31,248 mcg/24 hour

5-Pregnenetriol: 17-4,166 mcg/24 hour

5-Pregnenediol: 6-2,900 mcg/24 hour

Tetrahydro-11-Corticosterone: 13-1,548 mcg/24 hour

Tetrahydro-11-Deoxycorticosterone: <5-833 mcg/24 hour

Pregnanediol: 8-44,760 mcg/24 hour

17a-OH-Pregnanolone: 7-3,208 mcg/24 hour

Pregnanetriol: 50-9,768 mcg/24 hour

Pregnanetriolone: <5-139 mcg/24 hour

Tetrahydrodeoxycortisol: 7-1,047 mcg/24 hour

Cortisol: 11-642 mcg/24 hour

6B-OH-Cortisol: 22-2,061 mcg/24 hour

Tetrahydrocortisol: 185-16,515 mcg/24 hour

5a-Tetrahydrocortisol: 45-22,591 mcg/24 hour

B-Cortol: 28-4260 mcg/24 hour

11B-OH-Androsterone: 59-12,462 mcg/24 hour

11B-OH-Etiocholanolone: 32-6,354 mcg/24 hour

Cortisone: 19-749 mcg/24 hour

Tetrahydrocortisone: 262-32,461 mcg/24 hour

a-Cortolone: 207-13,931 mcg/24 hour

B-Cortolone: 63-7,489 mcg/24 hour

11-Oxoetiocholanolone: 63-7,449 mcg/24 hour

 

Females > or =50 years:

Androsterone: 32-10,134 mcg/24 hour

Etiocholanolone: 52-10,946 mcg/24 hour

Dehydroepiandrosterone: <5-10,046 mcg/24 hour

16a-OH-Dehydroepiandrosterone: <5-9,982 mcg/24 hour

5-Pregnenetriol: 10-1,901 mcg/24 hour

5-Pregnenediol: <5-2,732 mcg/24 hour

Tetrahydro-11-Corticosterone: 14-1,229 mcg/24 hour

Tetrahydro-11-Deoxycorticosterone: <5-123 mcg/24 hour

Pregnanediol: 8-2,138 mcg/24 hour

17a-OH-Pregnanolone: <5-571 mcg/24 hour

Pregnanetriol: 26-3,444 mcg/24 hour

Pregnanetriolone: <5-348 mcg/24 hour

Tetrahydrodeoxycortisol: 8-801 mcg/24 hour

Cortisol: 9-336 mcg/24 hour

6B-OH-Cortisol: 25-1,365 mcg/24 hour

Tetrahydrocortisol: 237-14,050 mcg/24 hour

5a-Tetrahydrocortisol: 92-12,604 mcg/24 hour

B-Cortol: 29-3289 mcg/24 hour

11B-OH-Androsterone: 86-9,280 mcg/24 hour

11B-OH-Etiocholanolone: 40-7,002 mcg/24 hour

Cortisone: 15-555 mcg/24 hour

Tetrahydrocortisone: 359-24,320 mcg/24 hour

a-Cortolone: 125-17,472 mcg/24 hour

B-Cortolone: 82-5,784 mcg/24 hour

11-Oxoetiocholanolone: 78-6,571 mcg/24 hour

 

Reference values have not been established for patients who are younger than 18 years of age.

Interpretation
Provides information to assist in interpretation of the test results

Test provides clinical risk values based on clinical data alone as well as integrated risk values based on clinical data in combination with biochemical steroid data. Reported risk values correspond to the probability of a malignant adrenal cortical carcinoma (ACC) or other malignancy (eg, sarcoma, lymphoma) as well as the probability of a benign mass (eg, adenoma, myelolipoma, cyst).

 

Test results provide the referring physician with probabilities for a variety of outcomes, thereby aiding the interpretation of clinical status and optimal paths for further investigation, if any, based on an informed discussion between provider and patient. Test results should always be interpreted in conjunction with all other clinical findings as they cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

 

See Adrenal Mass Panel Clinical Data Definition of Malignancy Predictors in Special Instructions.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Test not offered for pediatric patients. Risk assessments based off of adult populations.

 

Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease. This test should not form the sole basis for a diagnosis or treatment decision as results must be interpreted within the clinical context of the patient and should always be used in conjunction with clinical findings.

 

This test may be difficult to interpret in pregnant women and in patients with severe impairment of liver or kidney function.

 

Risk assignments for other malignancy may not be as accurate as risk assignment for adrenal cortical carcinoma (ACC) or adrenal cortical adenoma (ACA).

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Arlt W, Biehl M, Taylor AE, et al: Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab.2011 Dec;96(12):3775-3784. doi: 10.1210/jc.2011-1565

2. Hines JM, Bancos I, Bancos C, et al: High-Resolution, Accurate-Mass (HRAM) Mass Spectrometry Urine Steroid Profiling in the Diagnosis of Adrenal Disorders. Clin Chem. 2017 Dec;63(12):1824-1835. doi: 10.1373/clinchem.2017.271106

3. Bancos I, Arlt W: Diagnosis of a malignant adrenal mass: the role of urinary steroid metabolite profiling. Curr Opin Endocrinol Diabetes Obes. 2017 Jun;24(3):200-207. doi: 10.1097/MED.0000000000000333

4. Fassnacht M, Arlt W, Bancos I, et al: Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016 Aug;175(2):G1-G34. doi: 10.1530/EJE-16-0467

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Method Description
Describes how the test is performed and provides a method-specific reference

Steroids and their metabolites are extracted and analyzed with internal standard for detection by liquid chromatography-tandem mass spectrometry, high-resolution accurate mass (LC-MS/MS HRAM).(Unpublished Mayo method)

 

Clinical predictors and steroid data are algorithmically integrated to give a likelihood of adrenal cortical carcinoma, other malignancy, or benign mass.

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

7 to 17 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

14 months

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

0015M

LOINC® Information

Test Id Test Order Name Order LOINC Value
ACC Adrenal Mass Panel, 24 Hr, U 95556-7
Result Id Test Result Name Result LOINC Value
Result LOINC Value Tooltip
607276 ACC - Clinical Risk 95787-8
607277 Other Malignancy - Clinical Risk 95788-6
607278 Benign Mass - Clinical Risk 95789-4
607279 ACC - Integrated Risk 95790-2
607280 Other Malignancy - Integrated Risk 95791-0
607281 Benign Mass - Integrated Risk 95792-8
607282 Interpretation 73884-9
607333 Comment 77202-0
AC1AG Age at Diagnosis 63932-8
AC2GD Gender 76691-5
AC3MD Mode of Discovery 95557-5
AC4TZ Tumor Diameter (mm) 21889-1
AC5HX Unenhanced CT (Hounsfield Units) 95558-3
AC6HM Hormonal Excess 95559-1
TM66 Collection Duration 13362-9
VL66 Urine Volume 3167-4
607283 Androsterone 6705-8
607284 Androsterone Z-score 95560-9
607285 Etiocholanolone 2268-1
607286 Etiocholanolone Z-score 95561-7
607287 Dehydroepiandrosterone 13612-7
607288 Dehydroepiandrosterone Z-score 95562-5
607289 16a-OH-Dehydroepiandrosterone 95563-3
607290 16a-OH-DHEA Z-score 95564-1
607291 5-Pregnenetriol 95565-8
607292 5-Pregnenetriol Z-score 95566-6
607293 5-Pregnenediol 95567-4
607294 5-Pregnenediol Z-score 95568-2
607295 Tetrahydro-11-Corticosterone 95569-0
607296 TH-11-Corticosterone Z-score 95570-8
607297 Tetrahydro-11-Deoxycorticosterone 95571-6
607298 TH-11-Deoxycorticosterone Z-score 95572-4
607299 Pregnanediol 2834-0
607300 Pregnanediol Z-score 95573-2
607301 17a-OH-Pregnanolone 95574-0
607302 17a-OH-Pregnanolone Z-score 95575-7
607303 Pregnanetriol 2836-5
607304 Pregnanetriol Z-score 95576-5
607305 Pregnanetriolone 50643-6
607306 Pregnanetriolone Z-score 95577-3
607307 Tetrahydrodeoxycortisol 2996-7
607308 Tetrahydrodeoxycortisol Z-score 95578-1
607309 Cortisol 14158-0
607310 Cortisol Z-score 95579-9
607311 6B-OH-Cortisol 13611-9
607312 6B-OH-Cortisol Z-score 95580-7
607313 Tetrahydrocortisol 2995-9
607314 Tetrahydrocortisol Z-score 95581-5
607315 5a-Tetrahydrocortisol 21044-3
607316 5a-Tetrahydrocortisol Z-score 95582-3
607317 B-Cortol 53634-2
607318 B-Cortol Z-score 95583-1
607319 11B-OH-Androsterone 6701-7
607320 11B-OH-Androsterone Z-score 95584-9
607321 11B-OH-Etiocholanolone 6700-9
607322 11B-OH-Etiocholanolone Z-score 95585-6
607323 Cortisone 14044-2
607324 Cortisone Z-score 95586-4
607325 Tetrahydrocortisone 16116-6
607326 Tetrahydrocortisone Z-score 95587-2
607327 a-Cortolone 55906-2
607328 a-Cortolone Z-score 95588-0
607329 B-Cortolone 95589-8
607330 B-Cortolone Z-score 95590-6
607331 11-Oxoetiocholanolone 6703-3
607332 11-Oxoetiocholanolone Z-score 95591-4

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports